<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664985</url>
  </required_header>
  <id_info>
    <org_study_id>IPR_HYDRAMUC_17</org_study_id>
    <nct_id>NCT04664985</nct_id>
  </id_info>
  <brief_title>Evaluation of Mucogyne® Ovule in Vulvovaginal Dryness Management in Women Treated by Brachytherapy and/or Radiotherapy for Endometrial or Cervical Cancer.</brief_title>
  <acronym>HYDRAMUC</acronym>
  <official_title>Evaluation of Mucogyne® Ovule in Vulvovaginal Dryness Management in Women Treated by Brachytherapy and/or Radiotherapy for Endometrial or Cervical Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires IPRAD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Créapharm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Alfred Fournier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axonal-Biostatem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoires IPRAD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open-label, national (France), multicenter, prospective clinical study, to&#xD;
      evaluate the superiority of Mucogyne® ovules over the control group on vaginal health&#xD;
      (including hydration) in women treated by brachytherapy and/or radiotherapy for endometrial&#xD;
      or cervical cancer.&#xD;
&#xD;
      The study will be carried out in 2 phases: the first part will focus on 80 women with&#xD;
      endometrial cancer, an interim analysis will determine the interest of continuing or not the&#xD;
      study (second part) on the whole targeted population (endometrial or cervical cancer).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In the first part of the study, 80 women with endometrial cancer will be recruited over 8 months, 40 being randomized in the Mucogyne® arm, the 40 others in the control arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal Health Index (VHI) change from inclusion to end of study</measure>
    <time_frame>3 Months</time_frame>
    <description>Each parameter is evaluated from 1 (worst) to 5 (best/normal):&#xD;
vaginal elasticity,&#xD;
vaginal secretion volume,&#xD;
vaginal pH,&#xD;
epithelial mucous membrane integrity,&#xD;
vaginal hydration/lubrication.&#xD;
The sum of points for each parameter gives the VHI, from 5 (worst) to 25 (best/normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal mucosa scarring evolution</measure>
    <time_frame>3 Months</time_frame>
    <description>Evolution of scarring of the vaginal mucosa by a composite score:&#xD;
visualization of the hysterectomy scar (not visible / visible) for endometrial cancer patients OR visualization of the cervix (not visible / visible) for cervical cancer patients,&#xD;
presence or absence of vaginal adhesions / cohalescences (walls and bottom of the vagina ),&#xD;
collapse of adhesions to touch (Y / N),&#xD;
edema / redness of vaginal mucosa (indicative of inflammation),&#xD;
pain caused by pressure (Y / N),&#xD;
bleeding caused by contact (none / moderate / severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to additional local treatment administration</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) on vaginal health</measure>
    <time_frame>3 Months</time_frame>
    <description>Auto-evaluation: score from 1 (very much improved) to 7 (very much worse) on vaginal health related to the study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms (pain, dyspareunia, vaginal pruritis, vulvovaginal dryness) evolution</measure>
    <time_frame>3 Months</time_frame>
    <description>Auto-evaluation of the symptoms: pain, dyspareunia, vaginal pruritis, vulvovaginal dryness on Visual Analogic Scale (VAS) of 10mm&#xD;
Patient indicates where she locates the intensity of the symptom from 0mm (no symptom) to 10mm (worst intensity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VHI change at each visit</measure>
    <time_frame>3 Months</time_frame>
    <description>Each parameter is evaluated from 1 (worst) to 5 (best/normal):&#xD;
vaginal elasticity,&#xD;
vaginal secretion volume,&#xD;
vaginal pH,&#xD;
epithelial mucous membrane integrity,&#xD;
vaginal hydration/lubrication. The sum of points for each parameters gives the VHI, from 5 (worst) to 25 (best/normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal flora composition (Nugent score) evolution</measure>
    <time_frame>3 Months</time_frame>
    <description>Measured on vaginal sample collected at inclusion, 1 month and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications and adverse events</measure>
    <time_frame>3 Months</time_frame>
    <description>Complications and adverse events related to study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction questionnaire at the end of study</measure>
    <time_frame>3 Months</time_frame>
    <description>All patients (both arms) will be asked about their satisfaction on the treatment of their vulvogainal symptoms during the study will be assessed using a 5-point Likert scale :&#xD;
&quot;At the end of this study, how would you rate your level of satisfaction with the treatment of your vulvovaginal symptoms? Very satisfactory / Satisfactory / Moderate / Poor / Very Poor&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Vaginal Disease</condition>
  <arm_group>
    <arm_group_label>Mucogyne®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment for this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucogyne® ovule</intervention_name>
    <description>hyaluronic acid, vaginal ovule</description>
    <arm_group_label>Mucogyne®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman over 18&#xD;
&#xD;
          -  For the first phase of the study (first 80 patients): hysterectomized patient with&#xD;
             endometrial cancer (stage I, stage II and histological type I, without chemotherapy,&#xD;
             with brachytherapy and/or radiotherapy)&#xD;
&#xD;
          -  For the second phase of the study (142 following patients): patient with endometrial&#xD;
             cancer (stage I, stage II and histological type I, hysterectomized without&#xD;
             chemotherapy, with brachytherapy and/or radiotherapy) or with cervical cancer (stage&#xD;
             1B2 to 3B with or without chemotherapy, with brachytherapy and/or radiotherapy)&#xD;
&#xD;
          -  Vulvovaginal dryness confirmed by VHI &lt;15&#xD;
&#xD;
          -  Patient capable of receiving and understanding information related to the study,&#xD;
             giving informed written consent, and easily completing a quality of life questionnaire&#xD;
&#xD;
          -  Patient affiliated to the French social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with clinically observed vulvovaginal infections&#xD;
&#xD;
          -  Patient with endometrial cancer treated with chemotherapy&#xD;
&#xD;
          -  Patient already participating in another study&#xD;
&#xD;
          -  Patient under legal protection, or under guardianship or curatorship&#xD;
&#xD;
          -  For the second phase of the study (142 following patients) and only for patients with&#xD;
             cervical cancer: pregnancy (pregnancy test to be performed if premenopausal)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chru Besancon - Site 002</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes - Site 003</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Caremeau - Site 001</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - Site 005</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine - Site 004</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy - Site 006</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal dryness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

